Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation Following Endothelial Injury

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1990 May 1

PMID 2339120

Citations 33

Authors

E R Edelman

D H Adams

M J Karnovsky

Affiliations

Soon will be listed here.

Abstract

Continuous intravenous infusion of heparin suppresses smooth muscle cell proliferation in rats after endothelial injury but may lead to hemorrhage and other complications. The anticoagulant property has been removed from chemically modified heparin without loss of antiproliferative effect but use of such compounds is still limited. In this study ethylene-vinyl acetate copolymer matrices containing standard and modified heparin were placed adjacent to rat carotid arteries at the time of balloon dendothelialization. After 14 days arterial occlusion by smooth muscle cell proliferation was defined. Matrix delivery of both heparin compounds effectively diminished this proliferation in comparison to controls without producing systemic anticoagulation or side effects. In addition, this mode of therapy appeared more effective than the administration of the same agents by either intravenous pumps or heparin/polymer matrices placed in a subcutaneous site distant from the injured carotid artery. Thus, heparin's inhibition of smooth muscle cell proliferation after vascular injury might be most effective within the microenvironment of the injured vessel wall, and the accelerated atherosclerosis or restenosis that often follows angioplasty and other vascular interventions might best be treated with site-specific therapy.

Citing Articles

Treatment of Peripheral Artery Disease Using Injectable Biomaterials and Drug-Coated Balloons: Safety and Efficacy Perspective.

Qamar S, Spahic L, Benolic L, Zivanovic M, Filipovic N Pharmaceutics. 2023; 15(7).

PMID: 37514000 PMC: 10385947. DOI: 10.3390/pharmaceutics15071813.

Bindarit encapsulated nanoparticles prevent venous neointimal hyperplasia and restenosis in a murine angioplasty model.

Singh A, Kilari S, Cai C, Misra S Transl Res. 2022; 248:68-86.

PMID: 35914678 PMC: 11702511. DOI: 10.1016/j.trsl.2022.06.002.

Adventitial delivery of nanoparticles encapsulated with 1α, 25-dihydroxyvitamin D attenuates restenosis in a murine angioplasty model.

Cai C, Kilari S, Zhao C, Singh A, Simeon M, Misra A Sci Rep. 2021; 11(1):4772.

PMID: 33637886 PMC: 7910622. DOI: 10.1038/s41598-021-84444-x.

Evolution of drug-eluting biomedical implants for sustained drug delivery.

Quarterman J, Geary S, Salem A Eur J Pharm Biopharm. 2020; 159:21-35.

PMID: 33338604 PMC: 7856224. DOI: 10.1016/j.ejpb.2020.12.005.

Vascular Nanomedicine: Current Status, Opportunities, and Challenges.

Sun M, Sen Gupta A Semin Thromb Hemost. 2019; 46(5):524-544.

PMID: 31200393 PMC: 10071587. DOI: 10.1055/s-0039-1692395.

References

Stemerman M, Ross R . Experimental arteriosclerosis. I. Fibrous plaque formation in primates, an electron microscope study. J Exp Med. 1972; 136(4):769-89. PMC: 2139284. DOI: 10.1084/jem.136.4.769. View

Powell J, Clozel J, Muller R, Kuhn H, Hefti F, Hosang M . Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989; 245(4914):186-8. DOI: 10.1126/science.2526370. View

Clowes A, Karnowsky M . Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977; 265(5595):625-6. DOI: 10.1038/265625a0. View

Guyton J, Rosenberg R, Clowes A, Karnovsky M . Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980; 46(5):625-34. DOI: 10.1161/01.res.46.5.625. View

Somogyi P, Takagi H . A note on the use of picric acid-paraformaldehyde-glutaraldehyde fixative for correlated light and electron microscopic immunocytochemistry. Neuroscience. 1982; 7(7):1779-83. DOI: 10.1016/0306-4522(82)90035-5. View

Clowes A, Reidy M, Clowes M . Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983; 49(3):327-33. View

Brown L, Wei C, Langer R . In vivo and in vitro release of macromolecules from polymeric drug delivery systems. J Pharm Sci. 1983; 72(10):1181-5. DOI: 10.1002/jps.2600721019. View

Castellot Jr J, Beeler D, Rosenberg R, Karnovsky M . Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol. 1984; 120(3):315-20. DOI: 10.1002/jcp.1041200309. View

Gundry S, Klein M, Drongowski R, Kirsh M . Clinical evaluation of a new rapid heparin assay using the dye azure A. Am J Surg. 1984; 148(2):191-4. DOI: 10.1016/0002-9610(84)90219-8. View

10.

Diaz-Flores L, Dominguez C . Relation between arterial intimal thickening and the vasa-vasorum. Virchows Arch A Pathol Anat Histopathol. 1985; 406(2):165-77. DOI: 10.1007/BF00737083. View

11.

Langer R, Siegel R, Brown L, Leong K, Kost J, EDELMAN E . Controlled release and magnetically modulated systems for macromolecular drugs. Ann N Y Acad Sci. 1985; 446:1-13. DOI: 10.1111/j.1749-6632.1985.tb18386.x. View

12.

Austin G, Ratliff N, Hollman J, Tabei S, Phillips D . Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985; 6(2):369-75. DOI: 10.1016/s0735-1097(85)80174-1. View

13.

Bick R, Ross E . Clinical use of intrapulmonary heparin. Semin Thromb Hemost. 1985; 11(2):213-7. DOI: 10.1055/s-2007-1004377. View

14.

Langer R, Brown L, EDELMAN E . Controlled release and magnetically modulated release systems for macromolecules. Methods Enzymol. 1985; 112:399-422. DOI: 10.1016/s0076-6879(85)12032-x. View

15.

Habib J, Bossaller C, Wells S, Williams C, Morrisett J, Henry P . Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res. 1986; 58(2):305-9. DOI: 10.1161/01.res.58.2.305. View

16.

Larsen A, Lund D, Langer R, Folkman J . Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci U S A. 1986; 83(9):2964-8. PMC: 323427. DOI: 10.1073/pnas.83.9.2964. View

17.

Brown L, Munoz C, Siemer L, EDELMAN E, Langer R . Controlled release of insulin from polymer matrices. Control of diabetes in rats. Diabetes. 1986; 35(6):692-7. DOI: 10.2337/diab.35.6.692. View

18.

Whitworth H, Roubin G, Hollman J, Meier B, Leimgruber P, Douglas Jr J . Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1986; 8(6):1271-6. DOI: 10.1016/s0735-1097(86)80296-0. View

19.

Dawes J, Prowse C, Pepper D . Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res. 1986; 44(5):683-93. DOI: 10.1016/0049-3848(86)90169-6. View

20.

Castellot Jr J, Wright T, Karnovsky M . Regulation of vascular smooth muscle cell growth by heparin and heparan sulfates. Semin Thromb Hemost. 1987; 13(4):489-503. DOI: 10.1055/s-2007-1003525. View